Tiotropium bromide in the treatment of chronic obstructive pulmonary disease

Q4 Medicine Pulmonologiya Pub Date : 2023-12-13 DOI:10.18093/0869-0189-2023-33-6-810-818

O. N. Titova, N. Kuzubova, A. Kozyrev

{"title":"Tiotropium bromide in the treatment of chronic obstructive pulmonary disease","authors":"O. N. Titova, N. Kuzubova, A. Kozyrev","doi":"10.18093/0869-0189-2023-33-6-810-818","DOIUrl":null,"url":null,"abstract":"The aim of this review was to analyze current information on tiotropium bromide as one of the LAMAs. Tiotropium was chronologically the first LAMA in clinical practice. It is administered using a dry powder inhaler or an aerosol inhaler (Respimat soft mist inhaler). Due to the long bronchodilator effect, tiotropium can be inhaled once a day. The drug has a significant effect on functional respiratory parameters, reduces lung hyperinflation, improves exercise tolerance and quality of life. Tiotropium is superior to short-acting bronchodilators and long-acting β2-agonists (LABAs) and is comparable to other LAMAs, as well as combinations of LABAs and inhaled corticosteroids in the prevention of COPD exacerbations. Tiotropium bromide has a favorable safety profile. Generic tiotropium drug products, including Respium®, are currently available in the Russian Federation. A clinical trial confirmed the non-inferiority and safety of generic tiotropium drug compared to the original branded product.Conclusion. Tiotropium is an effective and safe medication for the maintenance treatment of COPD and for reducing COPD exacerbations. The generic tiotropium drug products widen the range of effective inhaled medications available to physicians.","PeriodicalId":37383,"journal":{"name":"Pulmonologiya","volume":"113 19","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18093/0869-0189-2023-33-6-810-818","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of this review was to analyze current information on tiotropium bromide as one of the LAMAs. Tiotropium was chronologically the first LAMA in clinical practice. It is administered using a dry powder inhaler or an aerosol inhaler (Respimat soft mist inhaler). Due to the long bronchodilator effect, tiotropium can be inhaled once a day. The drug has a significant effect on functional respiratory parameters, reduces lung hyperinflation, improves exercise tolerance and quality of life. Tiotropium is superior to short-acting bronchodilators and long-acting β2-agonists (LABAs) and is comparable to other LAMAs, as well as combinations of LABAs and inhaled corticosteroids in the prevention of COPD exacerbations. Tiotropium bromide has a favorable safety profile. Generic tiotropium drug products, including Respium®, are currently available in the Russian Federation. A clinical trial confirmed the non-inferiority and safety of generic tiotropium drug compared to the original branded product.Conclusion. Tiotropium is an effective and safe medication for the maintenance treatment of COPD and for reducing COPD exacerbations. The generic tiotropium drug products widen the range of effective inhaled medications available to physicians.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

噻托溴铵在慢性阻塞性肺病治疗中的应用

本综述旨在分析噻托溴铵作为一种 LAMA 的当前信息。从时间上看，噻托溴铵是第一种用于临床实践的 LAMA。它使用干粉吸入器或气雾吸入器（Respimat 软雾吸入器）给药。由于噻托溴铵具有较长的支气管扩张作用，因此可以每天吸入一次。噻托溴铵对呼吸功能参数有显著影响，可减少肺过度充气，提高运动耐受性和生活质量。在预防慢性阻塞性肺疾病加重方面，噻托溴铵优于短效支气管扩张剂和长效β2-激动剂（LABAs），与其他 LAMAs 以及 LABAs 和吸入皮质类固醇的联合用药效果相当。噻托溴铵具有良好的安全性。包括 Respium® 在内的非专利噻托溴铵药物产品目前在俄罗斯联邦有售。一项临床试验证实，与原品牌产品相比，非专利噻托溴铵的疗效和安全性均无劣势。噻托溴铵是一种有效、安全的药物，可用于慢性阻塞性肺疾病的维持治疗和减少慢性阻塞性肺疾病的恶化。噻托溴铵仿制药扩大了医生可使用的有效吸入药物的范围。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pulmonologiya Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The aim of this journal is to state a scientific position of the Russian Respiratory Society (RRS) on diagnosis and treatment of respiratory diseases based on recent evidence-based clinical trial publications and international consensuses. The most important tasks of the journal are: -improvement proficiency qualifications of respiratory specialists; -education in pulmonology; -prompt publication of original studies on diagnosis and treatment of respiratory diseases; -sharing clinical experience and information about pulmonology service organization in different regions of Russia; -information on current protocols, standards and recommendations of international respiratory societies; -discussion and consequent publication Russian consensus documents and announcement of RRS activities; -publication and comments of regulatory documents of Russian Ministry of Health; -historical review of Russian pulmonology development. The scientific concept of the journal includes publication of current evidence-based studies on respiratory medicine and their discussion with the participation of Russian and foreign experts and development of national consensus documents on respiratory medicine. Russian and foreign respiratory specialists including pneumologists, TB specialists, thoracic surgeons, allergists, clinical immunologists, pediatricians, oncologists, physiologists, and therapeutists are invited to publish article in the journal.